Hot on the heels of its recent $2.3bn deal with Blackstone Group, Inc. for the sale of its Japanese consumer healthcare business, Takeda Pharmaceutical Company Limited. is continuing apace with non-core divestments, despite passing its strategic goal for such deals following the acquisition of Shire Pharmaceuticals Group PLC.
Cheplapharm Benefits As Takeda Sheds More Older Products
$562m Deal Covers Mainly Canada, Europe
Japanese major presses on with post-Shire divestments even after passing strategic target.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.